NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

1. No, but ultimately this comes down to whether they are rational. If they are using the pending publication to screen off otherwise timely results then they are acting irrationally toward science, investors and regulators. I don't think they would do that over more than a short period of time -- say to get to the largest conference. Besides, I think the call is not NWBO's to make.

2. Probably not. Instead, the publication likely demonstrates, at minimum (when looked at AFTER topline in your scenario), the impact (or lack thereof) of DCVax-L on crossover. At maximum, it might show optimization impact on efficacy (or lack thereof) if changes were implemented during the trial.

imho.